Results 31 to 40 of about 4,026 (142)
Viruses, 2021 Hepatitis B virus (HBV) chronic infection causes progressive liver damage, although about 20% of patients develop extrahepatic manifestations such as cryoglobulinemic vasculitis (CV). Clinical manifestations range from mild to moderate (purpura, asthenia,
Cesare Mazzaro +11 more
doaj +1 more source
Safety and efficacy of entecavir for the treatment of chronic hepatitis B
, 2011 Melissa OsbornDepartment of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USAAbstract: Entecavir is a cyclopentyl deoxyguanosine analog that was approved for the treatment of the hepatitis B virus (HBV) in ...
Melissa Osborn
core +1 more source
Real World Use of the IL‐36 Receptor Antagonist Spesolimab: A Systematic Review and Analysis
JEADV Clinical Practice, EarlyView.ABSTRACT Background Spesolimab, an interleukin‐36 receptor antagonist, is approved for the treatment and prevention of generalised pustular psoriasis (GPP) flares. Its use has increasingly been reported in real‐world settings for both GPP and other inflammatory dermatoses.
Sophia A. Mense +4 more
wiley +1 more source
Annual Cost Thresholds for Entecavir and Tenofovir.
, 2015 ETV, entecavir; TDF, tenofovir; WTP, willingness to pay.Threshold between $6,800–20,400 according to the WHO 1-3x GDP for China.Annual Cost Thresholds for Entecavir and Tenofovir.
Samuel K. So (229078) +2 more
core +1 more source
Entecavir treatment in HBV-related decompensated cirrhosis
, 2011 Entecavir monotherapy has now been evaluated in patients with hepatitis B virus (HBV)-related decompensated cirrhosis. Entecavir achieves 1-year HBV DNA undetectability rates in up to 90% of treatment-naive patients in this setting without any case of ...
Alexopoulou, Alexandra +1 more
core +2 more sources
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Few prediction models have been specifically designed to evaluate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B and cirrhosis. This study aimed to develop a machine learning‐based prediction model to assess the risk of developing HCC in patients with hepatitis B virus (HBV)‐related cirrhosis undergoing nucleos(
Pao‐Yuan Huang +4 more
wiley +1 more source
Advances in Viral Markers for Predicting Functional Cure of Chronic Hepatitis B
Portal Hypertension &Cirrhosis, EarlyView.Functional cure, defined as sustained hepatitis B surface antigen (HBsAg) loss, is achieved by only a minority of patients with chronic hepatitis B (CHB); early identification of likely responders may improve cure rates and reduce costs. However, responses to antiviral therapy vary considerably, necessitating reliable hepatitis B virus (HBV) viral ...
Xinrong Lu +3 more
wiley +1 more source
Entecavir: a new treatment for chronic hepatitis B infection
, 2006 Hepatitis B virus can cause both acute and chronic liver disease in humans. Entecavir, a new, potent, orally administered guanosine analog for the treatment of chronic hepatitis B, has recently approved in the USA and Europe.
Schreibman, Ian R, Schiff, Eugene R
core +1 more source
Frontiers in PharmacologyObjectivesTo systematically evaluate the efficacy and safety of tenofovir and entecavir in chronic hepatitis B-related cirrhosis.MethodsA comprehensive search was conducted in databases including PubMed, Web of Science, Embase and Cochrane Library from ...
Lu Cao +4 more
doaj +1 more source